Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / IMMX - ImmixBio stock surges on positive data from preclinical trial of soft tissue sarcoma treatment

IMMX - ImmixBio stock surges on positive data from preclinical trial of soft tissue sarcoma treatment

Immix Biopharma Inc.
Immix Biopharma (NASDAQ:IMMX) on Friday announced positive data from animal study trial to test its lead candidate, IMX-110, ti treat Soft Tissue Sarcoma (STS). (IMMX) surged 60% before the bell. The study showed that after one cycle of treatment the drug produced 75% survival vs. 0% survival for J&J's STS drug Yondelis in a connective tissue cancer Soft Tissue Sarcoma mice study. In this study, IMX-110 was compared against approved drugs used to treat STS. "We believe this is a preview of anti-tumor activity to be demonstrated in our 2 clinical trials to be kicked-off in 2022: IMX-110 monotherapy, and IMX-110 in combination with anti-PD-1 tislelizumab," said Ilya Rachman, CEO of ImmixBio. The company believes STS is a $3 billion market, and is expected to grow to $6.5 billion by 2030.

For further details see:

ImmixBio stock surges on positive data from preclinical trial of soft tissue sarcoma treatment
Stock Information
Company Name: Immix Biopharma Inc.
Stock Symbol: IMMX
Market: NASDAQ
Website: immixbio.com
Menu
IMMX IMMX Quote IMMX Short IMMX News IMMX Articles IMMX Message Board
Get IMMX Alerts

News, Short Squeeze, Breakout and More Instantly...